Total Payments
$996,589
2024 Payments
$72,908
Companies
63
Transactions
2,534
Medicare Patients
21,285
Medicare Billing
$15.3M
Payment Breakdown by Category
Other$811,330 (81.4%)
Consulting$93,890 (9.4%)
Food & Beverage$58,860 (5.9%)
Travel$31,621 (3.2%)
Education$888.94 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $681,129 | 397 | 68.3% |
| Honoraria | $130,201 | 65 | 13.1% |
| Consulting Fee | $93,890 | 29 | 9.4% |
| Food and Beverage | $58,860 | 1,614 | 5.9% |
| Travel and Lodging | $31,621 | 383 | 3.2% |
| Education | $888.94 | 45 | 0.1% |
| Unspecified | $0 | 1 | 0.0% |
Payments by Type
General
$996,589
2,533 transactions
Ownership
$0
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $468,448 | 783 | $0 (2024) |
| Radius Health, Inc. | $84,362 | 151 | $0 (2024) |
| Horizon Therapeutics plc | $56,029 | 155 | $0 (2023) |
| Horizon Pharma plc | $52,768 | 116 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $44,486 | 89 | $0 (2024) |
| United Rheumatology | $41,798 | 8 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $39,512 | 69 | $0 (2024) |
| Celgene Corporation | $36,257 | 61 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $33,379 | 56 | $0 (2019) |
| Mallinckrodt Enterprises LLC | $29,483 | 74 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $72,908 | 244 | Amgen Inc. ($49,230) |
| 2023 | $83,181 | 275 | Amgen Inc. ($31,963) |
| 2022 | $71,051 | 285 | Amgen Inc. ($53,159) |
| 2021 | $77,488 | 142 | Amgen Inc. ($32,805) |
| 2020 | $80,349 | 128 | Amgen Inc. ($32,017) |
| 2019 | $245,006 | 508 | Amgen Inc. ($130,372) |
| 2018 | $223,585 | 531 | Amgen Inc. ($77,406) |
| 2017 | $143,021 | 421 | Amgen Inc. ($61,497) |
All Payment Transactions
2,534 individual payment records from CMS Open Payments — Page 1 of 102
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: Bone Health | ||||||
| 12/19/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $19.76 | General |
| Category: Bone Health | ||||||
| 12/19/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $7.01 | General |
| Category: Immunology | ||||||
| 12/18/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $27.92 | General |
| Category: IMMUNOLOGY | ||||||
| 12/14/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Education | In-kind items and services | $54.99 | General |
| Category: Cardiology | ||||||
| 12/11/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $28.43 | General |
| Category: Immunology | ||||||
| 12/11/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $19.19 | General |
| Category: Bone Health | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $26.26 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $75.71 | General |
| 12/05/2024 | Lilly USA, LLC | TALTZ (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $27.64 | General |
| Category: Immunology | ||||||
| 12/04/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $28.88 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $20.46 | General |
| Category: Immunology | ||||||
| 12/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,350.00 | General |
| 11/26/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $31.49 | General |
| Category: IMMUNOLOGY | ||||||
| 11/26/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $19.69 | General |
| Category: Dermatology | ||||||
| 11/25/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,625.00 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $22.54 | General |
| Category: Immunology | ||||||
| 11/16/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $113.66 | General |
| Category: Immunology | ||||||
| 11/15/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $133.89 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/15/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $83.65 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 11/14/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $24.57 | General |
| Category: Immunology | ||||||
| 11/13/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $125.01 | General |
| Category: Immunology | ||||||
| 11/13/2024 | DePuy Synthes Sales Inc. | ORTHOVISC (Device), MONOVISC | Food and Beverage | In-kind items and services | $24.77 | General |
| Category: Sports Early Intervention | ||||||
| 11/13/2024 | Amgen Inc. | EVENITY (Biological) | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: Bone Health | ||||||
| 11/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 29 | 3,997 | 300,657 | $9.8M | $3.1M |
| 2022 | 33 | 5,568 | 386,524 | $14.8M | $4.1M |
| 2021 | 36 | 5,709 | 336,654 | $14.5M | $4.1M |
| 2020 | 35 | 6,011 | 299,536 | $13.8M | $3.9M |
Total Patients
21,285
Total Services
1,323,371
Medicare Billing
$15.3M
Procedure Codes
133
All Medicare Procedures & Services
133 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 619 | 58,920 | $3.2M | $1.1M | 33.4% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 68 | 76,860 | $1.1M | $608,014 | 55.5% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 34 | 12,375 | $1.6M | $417,259 | 26.8% |
| J3262 | Injection, tocilizumab, 1 mg | Office | 2023 | 30 | 71,721 | $717,210 | $334,722 | 46.7% |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2023 | 46 | 71,600 | $1.8M | $280,018 | 15.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 869 | 1,610 | $482,800 | $170,434 | 35.3% |
| J3304 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | Office | 2023 | 36 | 2,528 | $158,000 | $33,507 | 21.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 59 | 217 | $86,800 | $27,272 | 31.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 164 | 164 | $65,600 | $23,908 | 36.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 746 | 1,666 | $99,960 | $21,664 | 21.7% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 372 | 373 | $130,550 | $16,959 | 13.0% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 71 | 162 | $72,900 | $14,693 | 20.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 61 | 202 | $35,350 | $12,468 | 35.3% |
| 77085 | Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment | Office | 2023 | 191 | 191 | $66,850 | $11,758 | 17.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 27 | 166 | $33,200 | $11,648 | 35.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 69 | 89 | $17,800 | $5,776 | 32.5% |
| 73551 | X-ray of thigh bone, 1 view | Office | 2023 | 82 | 164 | $16,400 | $4,060 | 24.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 18 | 114 | $17,100 | $3,060 | 17.9% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 39 | 39 | $3,120 | $2,805 | 89.9% |
| 76942 | Ultrasonic guidance for needle placement | Office | 2023 | 35 | 48 | $19,200 | $2,500 | 13.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 41 | 41 | $1,640 | $1,475 | 90.0% |
| 20526 | Injection of carpal tunnel | Office | 2023 | 14 | 19 | $3,800 | $1,444 | 38.0% |
| 20550 | Injection into tendon or ligament | Office | 2023 | 22 | 28 | $5,600 | $1,416 | 25.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $3,600 | $1,027 | 28.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 16 | 50 | $3,750 | $734.50 | 19.6% |
About Dr. Barry Gruber, M.D
Dr. Barry Gruber, M.D is a Rheumatology healthcare provider based in Babylon, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1710912431.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Barry Gruber, M.D has received a total of $996,589 in payments from pharmaceutical and medical device companies, with $72,908 received in 2024. These payments were reported across 2,534 transactions from 63 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($681,129).
As a Medicare-enrolled provider, Gruber has provided services to 21,285 Medicare beneficiaries, totaling 1,323,371 services with total Medicare billing of $15.3M. Data is available for 4 years (2020–2023), covering 133 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Babylon, NY
- Active Since 07/11/2006
- Last Updated 06/16/2010
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1710912431
Products in Payments
- Prolia (Biological) $256,346
- EVENITY (Biological) $144,687
- Tymlos (Biological) $83,848
- KRYSTEXXA (Biological) $70,476
- KRYSTEXXA (Drug) $52,263
- Otezla (Drug) $48,502
- ORENCIA (Biological) $40,618
- Zilretta (Drug) $35,227
- ACTHAR (Biological) $31,369
- KEVZARA (Biological) $21,258
- KEVZARA SARILUMAB INJECTION (Biological) $18,605
- RINVOQ (Biological) $14,088
- KEVZARA (Drug) $14,007
- OFEV (Drug) $13,032
- SIMPONI ARIA (Biological) $11,246
- STELARA (Biological) $10,878
- TREMFYA (Drug) $1,376
- Cimzia (Drug) $1,293
- XELJANZ (Drug) $1,192
- BENLYSTA (Biological) $747.78
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.